Isoform-Selective PI3K/AKT Pathway Inhibition & High-Purity Kinase Reagents for Oncology, Overgrowth Syndromes, and Neurological Disorders.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for AKT3 drug discovery. The product portfolio includes wild-type and mutant (E17K) recombinant proteins, lentivirus for stable cell lines, isoform-specific antibodies, and siRNA for validation. Related targets for counter-screening and pathway analysis are also available.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT) | AKT3 Kinase Domain (WT) Recombinant Protein. High purity (>95%), Sequence Verified, ATP-binding competent. | View AKT3 Products |
| Antigen (Mutant) | AKT3 E17K Mutant Protein (constitutively active). HEK293 expressed, Endotoxin <1 EU/µg. | View AKT3 Products |
| Gene Delivery | AKT3 Promise-ORF / Lentivirus. Full-length ORF for stable cell line construction. | View AKT3 Products |
| Benchmark Ab | Anti-AKT3 (Isoform-Specific). Recombinant monoclonal for Western / ELISA. | View AKT3 Products |
| Validator | AKT3 siRNA Set (3 unique sequences). For knockdown verification and specificity controls. | View AKT3 Products |
| Counter-Screen A | AKT1 Kinase Domain Protein. Essential for isoform selectivity assays. | View AKT1 Products |
| Counter-Screen B | AKT2 Kinase Domain Protein. Required for off-target liability assessment (hyperglycemia risk). | View AKT2 Products |
| Pathway Partner | PIK3CA (p110α) Kinase. Upstream activator for pathway reconstitution. | View PIK3CA Products |
| Related Target | PTEN. Tumor suppressor; PTEN loss drives AKT hyperactivation. | View PTEN Products |
| Related Target | mTOR. Downstream effector for combination therapy evaluation. | View mTOR Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (AKT1/AKT2 vs AKT3) | Human AKT1/AKT2/AKT3 Kinase Domain Proteins available as matched set; >95% purity; identical HEK293 expression system for consistent glycosylation and folding. |
| Drug Resistance Mutation Profiling | AKT3 E17K and emerging resistance mutants available as recombinant proteins; sequence verified by mass spec and endotoxin controlled. |
| ATP Competition & Binding Kinetics | High specific activity preparations with validated ATP binding sites; suitable for SPR and ITC. |
| Intracellular Target Validation (PROTAC/Stability) | Lentivirus particles for stable AKT3-overexpression cell lines; Endotoxin <1EU/μg. |
| Subfamily Counter Screening & Lack of Controls | Homolog panel proteins (AKT1, AKT2, AKT3) rigorously purified; recombinant positive control antibodies included. |
| False Positives in Pathway Analysis | Validated siRNA included for specificity checks and target-dependency confirmation. |
Global Clinical Landscape & Future Outlook
The AKT3 isoform has emerged as a critical node in precision oncology, distinct from pan-AKT inhibition strategies. Unlike AKT1 (ubiquitous) and AKT2 (metabolic/insulin signaling), AKT3 shows restricted expression patterns with prominent roles in melanoma (BRAF/MEK inhibitor resistance), triple-negative breast cancer (TNBC), prostate cancer metastasis, and rare overgrowth syndromes (MPPH2). The race for PI3K/AKT/mTOR pathway therapeutics is intensifying, with major players shifting focus from traditional pan-AKT small molecule inhibitors (e.g., capivasertib, ipatasertib) to highly selective isoform-specific inhibitors and targeted protein degraders (PROTACs). While first-generation pan-AKT inhibitors have demonstrated efficacy, their clinical utility is often limited by dose-limiting toxicities, notably hyperglycemia driven by AKT2 inhibition. As these therapies navigate the clinic, the next wave of R&D is heavily targeting AKT3-specific inhibition for melanomas, brain tumors, and neurological disorders, as well as developing dual-mechanism modalities to bypass acquired kinase resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Pan-AKT Small Molecule Inhibitor | AstraZeneca, Roche, Bayer | Breast Cancer, Prostate Cancer | Isoform Selectivity Assay (Need AKT1/2/3 High-Purity Panel) |
| Isoform-Selective Small Molecule | Emerging Biotech / Pharma | Melanoma, TNBC, CNS Disorders | Mutant vs WT Binding (Need E17K & Kinase Domain Mutant Proteins) |
| PROTAC Degrader | Arvinas, Kymera, C4 Therapeutics | Solid Tumors, Resistance Reversal | Cell-based Stability Assay (Need High-titer Lentivirus for Stable Lines) |
| Allosteric Inhibitor | Merck, Novartis | PTEN-deficient Tumors, Prostate Cancer | PH Domain / Full-Length Protein (Need constructs for SPR binding) |
| Combination (PI3K+AKT3 / AKT3+MEK) | Genentech, Incyte | Resistant Cancers | Pathway Reconstitution (Need PIK3CA + AKT3 proteins) |
| RNAi / ASO | Alnylam, Ionis | Rare Overgrowth Syndromes | Knockdown Efficacy (Need Sequence Verified Antibodies & Controls) |
Live AKT3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly: